Invention Grant
- Patent Title: Selective antisense compounds and uses thereof
-
Application No.: US16793119Application Date: 2020-02-18
-
Publication No.: US11236335B2Publication Date: 2022-02-01
- Inventor: Michael Oestergaard , Punit P. Seth , Eric E. Swayze
- Applicant: Ionis Pharmaceuticals, Inc.
- Applicant Address: US CA Carlsbad
- Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee Address: US CA Carlsbad
- Agency: McNeill Baur PLLC
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07H21/02 ; C12N15/113

Abstract:
The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
Public/Granted literature
- US20210002636A1 Selective Antisense Compounds and Uses Thereof Public/Granted day:2021-01-07
Information query